Literature DB >> 15340774

Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels.

Heinz Gögelein1, J Brendel, K Steinmeyer, C Strübing, N Picard, D Rampe, K Kopp, A E Busch, M Bleich.   

Abstract

Previous studies in pigs and goats have demonstrated that AVE0118 prolongs atrial refractoriness without any effect on the QT-interval. The purpose of the present study was to investigate the effect of the compound on various cardiac ion channels. AVE0118 blocked the pig Kv1.5 and the human Kv1.5 expressed in Xenopus oocytes with IC(50) values of 5.4+/-0.7 microM and 6.2+/-0.4 microM respectively. In Chinese hamster ovary (CHO) cells, AVE0118 decreased the steady-state hKv1.5 current with an IC(50) of 1.1+/-0.2 microM. The hKv4.3/KChIP2.2 current in CHO cells was blocked by AVE0118 by accelerating the apparent time-constant of inactivation ( tau(inact)), and the integral current was inhibited with an IC(50) of 3.4+/-0.5 microM. At 10 microM AVE0118 tau(inact) decreased from 9.3+/-0.6 ms ( n=8, control) to 3.0+/-0.3 ms ( n=8). The K(ACh) current was investigated in isolated pig atrial myocytes by application of 10 microM carbachol. At a clamp potential of -100 mV the I(KACh) was half-maximally blocked by 4.5+/-1.6 microM AVE0118. In the absence of carbachol, AVE0118 had no effect on the inward current recorded at -100 mV. Effects on the I(Kr) current were investigated on HERG channels expressed in CHO cells. AVE0118 blocked this current half-maximally at approximately 10 microM. Comparable results were obtained in isolated guinea pig ventricular myocytes, where half-maximal inhibition of the I(Kr) tail current occurred at a similar concentration of AVE0118. Other ionic currents, like the I(Ks), I(KATP) (recorded in guinea pig ventricular myocytes), and L-type Ca(2+) (recorded in pig atrial myocytes) were blocked by 10 microM AVE0118 by 10+/-3% ( n=6), 28+/-7% ( n=4), and 22+/-13% ( n=5) respectively. In summary, AVE0118 preferentially inhibits the atrial K(+) channels I(Kur), I(to) and I(KACH). This profile may explain the selective prolongation of atrial refractoriness described previously in pigs and goats.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15340774     DOI: 10.1007/s00210-004-0957-y

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  37 in total

1.  Modulation of A-type potassium channels by a family of calcium sensors.

Authors:  W F An; M R Bowlby; M Betty; J Cao; H P Ling; G Mendoza; J W Hinson; K I Mattsson; B W Strassle; J S Trimmer; K J Rhodes
Journal:  Nature       Date:  2000-02-03       Impact factor: 49.962

2.  Molecular cloning and characterization of two voltage-gated K+ channel cDNAs from human ventricle.

Authors:  M M Tamkun; K M Knoth; J A Walbridge; H Kroemer; D M Roden; D M Glover
Journal:  FASEB J       Date:  1991-03-01       Impact factor: 5.191

3.  Role of the Kv4.3 K+ channel in ventricular muscle. A molecular correlate for the transient outward current.

Authors:  J E Dixon; W Shi; H S Wang; C McDonald; H Yu; R S Wymore; I S Cohen; D McKinnon
Journal:  Circ Res       Date:  1996-10       Impact factor: 17.367

Review 4.  Myocardial potassium channels: electrophysiological and molecular diversity.

Authors:  D M Barry; J M Nerbonne
Journal:  Annu Rev Physiol       Date:  1996       Impact factor: 19.318

5.  Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes.

Authors:  J Feng; B Wible; G R Li; Z Wang; S Nattel
Journal:  Circ Res       Date:  1997-04       Impact factor: 17.367

6.  hKChIP2 is a functional modifier of hKv4.3 potassium channels: cloning and expression of a short hKChIP2 splice variant.

Authors:  N Decher; O Uyguner; C R Scherer; B Karaman; M Yüksel-Apak; A E Busch; K Steinmeyer; B Wollnik
Journal:  Cardiovasc Res       Date:  2001-11       Impact factor: 10.787

7.  Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current.

Authors:  D Fedida; B Wible; Z Wang; B Fermini; F Faust; S Nattel; A M Brown
Journal:  Circ Res       Date:  1993-07       Impact factor: 17.367

8.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.

Authors:  O P Hamill; A Marty; E Neher; B Sakmann; F J Sigworth
Journal:  Pflugers Arch       Date:  1981-08       Impact factor: 3.657

9.  Effects of a novel class III antiarrhythmic agent, NIP-142, on canine atrial fibrillation and flutter.

Authors:  Hidehiko Nagasawa; Akira Fujiki; Naoki Fujikura; Tomoyuki Matsuda; Toru Yamashita; Hiroshi Inoue
Journal:  Circ J       Date:  2002-02       Impact factor: 2.993

10.  Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents.

Authors:  Z Wang; B Fermini; S Nattel
Journal:  Circ Res       Date:  1993-12       Impact factor: 17.367

View more
  20 in total

1.  Targeting atrioventricular differences in ion channel properties for terminating acute atrial fibrillation in pigs.

Authors:  Sandeep V Pandit; Sharon Zlochiver; David Filgueiras-Rama; Sergey Mironov; Masatoshi Yamazaki; Steven R Ennis; Sami F Noujaim; Antony J Workman; Omer Berenfeld; Jerome Kalifa; José Jalife
Journal:  Cardiovasc Res       Date:  2010-11-13       Impact factor: 10.787

Review 2.  [New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers].

Authors:  U Ravens; E Wettwer; U Schotten; R Wessel; D Dobrev
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

3.  Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity.

Authors:  Alexander Burashnikov; Hector Barajas-Martinez; Dan Hu; Eyal Nof; Jonathan Blazek; Charles Antzelevitch
Journal:  J Cardiovasc Pharmacol       Date:  2012-06       Impact factor: 3.105

4.  AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog.

Authors:  Alexander Burashnikov; Andrew C Zygmunt; Jose M Di Diego; Gunilla Linhardt; Leif Carlsson; Charles Antzelevitch
Journal:  J Cardiovasc Pharmacol       Date:  2010-07       Impact factor: 3.105

5.  Effects of the novel amiodarone-like compound SAR114646A on cardiac ion channels and ventricular arrhythmias in rats.

Authors:  Heinz Goegelein; Patrick Gautier; Alain Roccon; Stephen O'Connor; Hartmut Ruetten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-07-16       Impact factor: 3.000

Review 6.  Small-molecule modulators of inward rectifier K+ channels: recent advances and future possibilities.

Authors:  Gautam Bhave; Daniel Lonergan; Brian A Chauder; Jerod S Denton
Journal:  Future Med Chem       Date:  2010-05       Impact factor: 3.808

Review 7.  Voltage-gated potassium channels as therapeutic targets.

Authors:  Heike Wulff; Neil A Castle; Luis A Pardo
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

8.  Depolarization and decreased surface expression of K+ channels contribute to NSAID-inhibition of intestinal restitution.

Authors:  L C Freeman; D F Narvaez; A McCoy; F B von Stein; S Young; K Silver; S Ganta; D Koch; R Hunter; R F Gilmour; J D Lillich
Journal:  Biochem Pharmacol       Date:  2007-04-04       Impact factor: 5.858

9.  Inhibition of IK,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation.

Authors:  Niels Voigt; Nadiia Rozmaritsa; Anne Trausch; Thomasz Zimniak; Torsten Christ; Erich Wettwer; Klaus Matschke; Dobromir Dobrev; Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-09-17       Impact factor: 3.000

Review 10.  New drugs for atrial fibrillation.

Authors:  Matthias Hammwöhner; Jan Smid; Uwe Lendeckel; Andreas Goette
Journal:  J Interv Card Electrophysiol       Date:  2008-06-06       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.